Quantum Biopharma Files 20-F, Reports Assets & Liabilities
Ticker: QNTM · Form: 20-F · Filed: Mar 28, 2025 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 20-F |
| Filed Date | Mar 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, annual-report, share-split, corporate-action
TL;DR
Quantum Biopharma 20-F is in: Assets ~$151.7M, Liabilities ~$151.6M. Share split & Celly distribution happened.
AI Summary
Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed its 20-F for the fiscal year ending December 31, 2024. The company, incorporated in A6 and headquartered in Toronto, Canada, reported total assets of $151,701,000 and total liabilities of $151,622,000. A significant event mentioned is the distribution of 45,712,529 shares of Celly to shareholders, following a 2:1 share split.
Why It Matters
This filing provides a year-end financial snapshot and details corporate actions like share splits and distributions, crucial for investors assessing the company's financial health and structure.
Risk Assessment
Risk Level: medium — The company has very thin margins between assets and liabilities, indicating potential financial fragility.
Key Numbers
- $151.7M — Total Assets (As of December 31, 2024)
- $151.6M — Total Liabilities (As of December 31, 2024)
- 45,712,529 — Celly Shares Distributed (Distributed to shareholders post-share split)
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Filer of the 20-F
- FSD Pharma Inc. (company) — Former name of Quantum Biopharma Ltd.
- 20241231 (date) — Fiscal year end
- Toronto, Canada (location) — Company headquarters
- 45,712,529 (dollar_amount) — Number of Celly shares distributed
- 2:1 (share_split) — Stock split ratio
FAQ
What is the net income or loss for Quantum Biopharma Ltd. for the fiscal year 2024?
The filing does not explicitly state the net income or loss in the provided snippet, but shows revenue of $1,517,010 and cost of revenue of $1,516,220, suggesting a very small gross profit.
What were the total revenues for Quantum Biopharma Ltd. in 2024?
Total revenues for the fiscal year ending December 31, 2024, were $1,517,010.
What is the company's cash and cash equivalents balance as of December 31, 2024?
Cash and cash equivalents are listed as $137,626,863 as of December 31, 2024.
What was the total number of shares outstanding before the 2:1 share split?
The filing indicates 151,701,000 shares outstanding before the 2:1 share split.
What is the company's primary business activity?
Quantum Biopharma Ltd. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on March 28, 2025 regarding Quantum Biopharma Ltd. (QNTM).